Search Results - "HORI, Mitsuo"

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A, Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S, Richardson, Paul G, Popa McKiver, Mihaela, Jou, Ying-Ming, Shelat, Suresh G, Robbins, Michael, Rafferty, Brian, San-Miguel, Jesús

“…In a randomized trial of pomalidomide plus dexamethasone with or without the immunostimulatory monoclonal antibody elotuzumab, the addition of elotuzumab…”
Get full text

Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL) by Wang, Yu, Tsukamoto, Yoshiyuki, Hori, Mitsuo, Iha, Hidekatsu

“…Diffuse Large B-cell Lymphoma (DLBCL), with its intrinsic genetic and epigenetic heterogeneity, exhibits significantly variable clinical outcomes among…”
Get full text

Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy by Suzuki, Atsushi, Kakugawa, Satoshi, Miyoshi, Masafumi, Hori, Mitsuo, Suzuki, Kenshi, Furukawa, Yusuke, Ohta, Kensuke

Get full text

Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells by Kikuchi, Jiro, Hori, Mitsuo, Osada, Naoki, Matsuoka, Sae, Suzuki, Atsushi, Kakugawa, Satoshi, Yasui, Hiroshi, Harada, Takeshi, Tenshin, Hirofumi, Abe, Masahiro, Nakasone, Hideki, Furukawa, Yusuke

Get full text

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A., Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S., Richardson, Paul G., Popa McKiver, Mihaela, Jou, Ying-Ming, Shelat, Suresh G., Robbins, Michael, Rafferty, Brian, San-Miguel, Jesús

Get full text

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan by Kubo, Kohmei, Hori, Mitsuo, Ohta, Kensuke, Handa, Hiroshi, Hatake, Kiyohiko, Matsumoto, Morio, Hagiwara, Shotaro, Ohashi, Kazuteru, Nakaseko, Chiaki, Suzuki, Kenshi, Ito, Shigeki, Kinoshita, Gen, Shelat, Suresh G., Miyoshi, Masafumi, Takezako, Naoki

“…Novel therapies are needed for patients with newly diagnosed multiple myeloma (NDMM). Elotuzumab plus lenalidomide and dexamethasone (ELd) is approved for the…”
Get full text

Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera by Kajikawa, Natsuki, Seki, Yoshimoto, Fujio, Takayuki, Okoshi, Yasushi, Hori, Mitsuo, Saito, Hitoaki, Iijima, Tatsuo, Kojima, Hiroshi

“…A 78-year-old man who had a 20-year history of polycythemia vera (PV) with a JAK2 V617F mutation presented with gradually progressive disturbance of…”
Get full text

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors by Wang, Yu, Shimosaki, Shunsuke, Ikebe, Emi, Iha, Hidekatsu, Yamamoto, Jun-Ichi, Fife, Nichole, Ichikawa, Tomonaga, Hori, Mitsuo, Ogata, Masao, Tsukamoto, Yoshiyuki, Hijiya, Naoki, Moriyama, Masatsugu, Hagiwara, Shotaro, Kusano, Shuichi, Saito, Masumichi, Ahmed, Kamruddin, Nishizono, Akira, Handa, Hiroshi, Morishita, Kazuhiro

“…Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an…”
Get full text

Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis by Fukushima, Masaya, Okoshi, Yasushi, Fukazawa, Keiko, Koshino, Mayuko, Ishiguro, Shingo, Mitsuhashi, Shoichi, Saitoh, Hitoaki, Iijima, Tatsuo, Kojima, Hiroshi, Hori, Mitsuo

“…A 55-year-old man presented to our department with diarrhea, weight loss, fatigability, and polyarthralgia. Blood tests revealed elevated soluble interleukin-2…”
Get full text

Commensal microbiota contributes to chronic endocarditis in TAX1BP1 deficient mice by Nakano, Satoko, Ikebe, Emi, Tsukamoto, Yoshiyuki, Wang, Yan, Matsumoto, Takashi, Mitsui, Takahiro, Yahiro, Takaaki, Inoue, Kunimitsu, Kawazato, Hiroaki, Yasuda, Aiko, Ito, Kanako, Yokoyama, Shigeo, Takahashi, Naohiko, Hori, Mitsuo, Shimada, Tatsuo, Moriyama, Masatsugu, Kubota, Toshiaki, Ono, Katsushige, Fujibuchi, Wataru, Jeang, Kuan-Teh, Iha, Hidekatsu, Nishizono, Akira

“…Tax1-binding protein 1 (Tax1bp1) negatively regulates NF-κB by editing the ubiquitylation of target molecules by its catalytic partner A20. Genetically…”
Get full text

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia by Yoshida, Chikashi, Komeno, Takuya, Hori, Mitsuo, Kimura, Tomofumi, Fujii, Masami, Okoshi, Yasushi, Suzukawa, Kazumi, Chiba, Shigeru, Hasegawa, Yuichi, Mukai, Harumi Yamamoto, Ito, Takayoshi, Shimizu, Seiichi, Kamoshita, Masaharu, Kudo, Daisuke, Shinagawa, Atsushi, Chikatsu, Norio, Monma, Yuriko, Watanabe, Norimichi, Kojima, Hiroshi

“…The correlation between imatinib (IM) trough plasma concentration (Cmin) and clinical response was assessed in patients with chronic-phase chronic myeloid…”
Get full text

Langerhans cell sarcoma of the cervical lymph node: A case report and literature review by Nakayama, Masahiro, Takahashi, Kuniaki, Hori, Mitsuo, Okumura, Toshiyuki, Saito, Mistuaki, Yamakawa, Mitsunori, Tabuchi, Keiji, Hara, Akira

“…Abstract Langerhans cell sarcoma (LCS), a neoplastic proliferation of Langerhans cells with malignant cytologic features, is a very rare disease. We report the…”
Get full text

Recycling of Polyethylene Terephthalate Using High-pressure Steam Treatment by Noritake, Ai, Hori, Mitsuo, Shigematsu, Mikiji, Tanahashi, Mitsuhiko

“…In this study, polyethylene terephthalate (PET) was broken into fine particles during high-pressure steam treatment without crushing or using acidic or…”
Get full text

A novel HSP90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL-like lymphocytes and provides extended survival period by Ikebe, Emi, Kawaguchi, Akira, Tezuka, Kenta, Taguchi, Shinya, Hirose, Satoshi, Matsumoto, Takashi, Mitsui, Takahiro, Senba, Kazuyo, Nishizono, Akira, Hori, Mitsuo, Hasegawa, Hiroo, Yamada, Yasuaki, Ueno, Takaharu, Tanaka, Yuetsu, Sawa, Hirofumi, Hall, William, Minami, Yasuaki, Jeang, Kuan-Teh, Ogata, Masao, Morishita, Kazuhiro, Hasegawa, Hideki, Fujisawa, Jun-ichi, Iha, Hidekatsu

Get full text

Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7 by Kikuchi, Jiro, Hori, Mitsuo, Iha, Hidekatsu, Toyama-Sorimachi, Noriko, Hagiwara, Shotaro, Kuroda, Yoshiaki, Koyama, Daisuke, Izumi, Tohru, Yasui, Hiroshi, Suzuki, Atsushi, Furukawa, Yusuke

“…SLAMF7 is expressed mainly on multiple myeloma (MM) cells and considered an ideal target for immunotherapeutic approaches. Indeed, elotuzumab, an anti-SLAMF7…”
Get full text

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial by Dimopoulos, Meletios A, Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S, Richardson, Paul G, Popa McKiver, Mihaela, Jou, Ying-Ming, Yao, David, Das, Prianka, San-Miguel, Jesús

“…In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved…”
Get full text

Comprehensive Analysis of Serum Cytokines/Chemokines in Myeloma Patients for Pursuing the Abnormality in Microenvironment and Predicting the Prognosis by Cho, Yukiko, Inada, Katsushige, Okoshi, Yasushi, Hori, Mitsuo, Kojima, Hiroshi

“…▪ Bone marrow microenvironment plays a crucial role for the development and progression of multiple myeloma (MM). To gain insights about the abnormality in…”
Get full text

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan by Takezako, Naoki, Ohta, Kensuke, Handa, Hiroshi, Hori, Mitsuo, Kinoshita, Gen, Shelat, Suresh, Miyoshi, Masafumi, Kubo, Kohmei

“…Introduction: Elotuzumab, a humanized IgG1 monoclonal antibody that binds to SLAMF7 expressed on myeloma and natural killer (NK) cells, has a dual mode of…”
Get full text

Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects by Nagasawa, Toshiro, Hasegawa, Yuichi, Shimizu, Seiichi, Kawashima, Yasuko, Nishimura, Shigeko, Suzukawa, Kazumi, Mukai, Harumi, Hori, Mitsuo, Komeno, Takuya, Kojima, Hiroshi, Ninomiya, Haruhiko, Tahara, Tomoyuki, Abe, Tsukasa

“…A patient with idiopathic thrombocytopenic purpura (ITP) developed T‐cell lymphoma while undergoing steroid therapy. We examined the relationship between the…”
Get full text

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study by Hori, Mitsuo, Takezako, Naoki, Sunami, Kazutaka, Ito, Shigeki, Kuroda, Junya, Popa-McKiver, Mihaela, Jou, Ying-Ming, Shelat, Suresh G., Miyoshi, Masafumi, Suzuki, Kenshi

“…Introduction: Multiple myeloma (MM) is largely incurable despite therapies such as proteasome inhibitors (PIs), immunomodulatory drugs, and monoclonal…”
Get full text